EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS

Аbstract.  Сlinical  and  immunocorrective  efficiency  of  Roncoleukin®  (IL-2)  monotherapy  applied  as subcutaneous injections versus inhalatory mode of treatment, was studied in patients with chronic recurrent infections. It was shown that administration of Roncoleukin® at a total dose of 1.5 m...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: O. I. Zheltova, N. M. Starostina, M. A. Tikhonova, O. Yu. Leplina, E. R. Chernykh, A. A. Ostanin
Formato: article
Lenguaje:RU
Publicado: SPb RAACI 2014
Materias:
Acceso en línea:https://doaj.org/article/cff50ac638bf4de78a946b0819458c87
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Аbstract.  Сlinical  and  immunocorrective  efficiency  of  Roncoleukin®  (IL-2)  monotherapy  applied  as subcutaneous injections versus inhalatory mode of treatment, was studied in patients with chronic recurrent infections. It was shown that administration of Roncoleukin® at a total dose of 1.5 mg was accompanied by increased activity of Th1 lymphocytes and reduced in vitro production of IL-10, and does not exert any adverse immunotropic effects associated with Treg expansion. In general, the positive clinical effect was registered in 65% (26/40) of the patients, and its duration ranged between 3 and 7 months (a mean of 4.4±0.2 months). Clinical  efficiency  of  Roncoleukin®  inhalations  proved  to  be  not  inferior  to  conventional  Roncoleukin® immunotherapy performed by subcutaneous injections (resp., 70 and 60% of positive responses), and allows a more significant prolongation of event-free remission. (Med. Immunol., 2011, vol. 13, N 2-3, pp 227-236)